LeMaitre Vascular, Inc.

LeMaitre Vascular, Inc. Earnings Recaps

LMAT Health Care 2 recaps
Next earnings: February 24, 2027 (estimated) · full calendar
Q3 2026 Nov 8, 2026

LeMaitre shares fell 5.0% after earnings, despite 12% organic sales growth. The likely concern is the cost of growth: operating expenses rose 18%, faster than sales, while full-year guidance calls for 11% organic growth—below Q3’s pace.

Key takeaways
  • Q3 organic sales grew 12%, comprising 7% price and 5% unit growth; reported sales growth was 11%, including a $440,000 negative FX impact.
  • Gross margin was 71.7%, up 90 basis points year over year; excluding a $0.5 million inventory reserve tied to the FAS-TIP discontinuation, it was 72.4%, up 160 basis points.
  • Operating expenses increased 18% to $31 million, with rep count up 13% to 171 and R&D spending up $1.1 million year over year. Operating margin was 26%.
  • Net income was $15 million and diluted EPS was $0.65. Free cash flow was $19.7 million, and cash and investments totaled $390 million at quarter-end.
  • Full-year guidance implies 11% organic sales growth and 18% EPS growth. LeMaitre also acquired B. Braun vascular assets for $19.2 million, including a portfolio with $9.4 million in 2025 sales.
Q1 2026 May 7, 2026

LeMaitre Vascular’s shares fell 3.7% post-earnings, reflecting investor disappointment despite solid sales and EPS growth, driven primarily by cautious gross margin guidance and deceleration in unit growth within the distribution business.

Key takeaways
  • Sales grew 11% in Q1, driven by an 8% price increase and 2% unit growth, with direct organic sales growing 12.8%; however, the distribution segment saw lower-than-average unit performance, weighing on growth.
  • Gross margin improved 350 basis points year-over-year to 72.7%, but Q2 guidance lowered margins to 72.1% due to new warehouse and tissue processing transfers, signaling near-term margin pressure.
  • Operating expenses rose 6% to $30.6 million despite a 3% overall headcount reduction; operating income increased 41% to $17.8 million with a 27% operating margin.
  • EPS grew 42% to $0.68, boosted by margin expansion and a structurally lower tax rate due to higher foreign-derived intangible income deductions.
  • Full-year revenue guidance affirmed at $280 million for 12% organic growth, but margin guidance only modestly raised, underscoring cautious outlook amid ongoing operational transitions.